<!DOCTYPE html>
<html lang="th">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Premedication for Antiemesis</title>
    <style>
        table {
            width: 100%;
            border-collapse: collapse;
        }
        th, td {
            border: 1px solid black;
            padding: 10px;
            text-align: center;
        }
        th {
            background-color: #f2f2f2;
        }
        .column1 {
            width: 50%; /* กำหนดสัดส่วนของคอลัมน์แรกเป็น 30% */
        }
        .column2 {
            width: 50%; /* กำหนดสัดส่วนของคอลัมน์ที่สองเป็น 70% */
        }
	.button-container {
            position: fixed;
            bottom: 16px;
            right: 16px;
            display: flex;
            gap: 10px; /* ระยะห่างระหว่างปุ่ม */
        }
	.btn {
            padding: 10px 20px;
            font-size: 16px;
            color: white;
            background-color: #007bff;
            border: none;
            border-radius: 5px;
            cursor: pointer;
            text-decoration: none;
        }
footer {
    background-color: #333;
    color: white;
    text-align: center;
    padding: 12px;
}

footer nav a {
    color: white;
    text-decoration: none;
    margin: 0 10px;
}
    </style>
</head>
<body>
<div class="button-container">
	<a href="index.html" class="btn">HOME</a>
	<a href="Search for Medication.html" class="btn">SEARCH</a>
	<a href="Premed.html" class="btn">TOP ↑</a></div>
    <h2>Premedication for Antiemesis</h2>
<a href="#section1">High Risk</a>☺☻☺<a href="#section2">Moderate Risk</a>☺☻☺<a href="#section3">Low Risk and Minimal</a>☺☻☺<a href="#section4">Breakthrough Treatment</a>
    <table>
	<tr>
		<th colspan="2" id="section1" style="background-color: #FF6F61;"><b>High Emesis Risk</b>
	</tr>
	<tr>
            <td class="column1"><b>Day 1</b></td>
            <td class="column2"><b>Day 2, 3, 4</b></td>
        </tr>
	<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option A</b></th>
	</tr>
        <tr>
            <td style="text-align:left;" valign="top"><ol>
	<li>Olanzapine 2.5-10 mg PO once daily (or bedtime)</li>		
	<li>NK1 receptor antagonist (RA) (choose one)	</li>	
		<ul type="square">
			<li>Aprepitant 125 mg PO once</li>	
			<li>Aprepitant injectable emulsion 130 mg intravenous (IV) once</li>	
			<li>Fosaprepitant 150 mg IV once</li>	
			<li>Netupitant 300 mg / palonosetron 0.5 mg (available as fixed combination product only) PO once</li>	
			<li>Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once</li>	
			<li>Rolapitant 180 mg PO once</li>
		</ul>	
	<li>5-HT3 RA (choose one)		
		<ul type="square">
			<li>Dolasetron 100 mg PO once</li>	
			<li>Granisetron 10 mg subcutaneous (SQ) once, or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of anticancer therapy</li>
			<li>Ondansetron 16–24 mg PO once, or 8–16 mg IV once</li>	
			<li>Palonosetron 0.25 mg IV once</li>	
	<li>Dexamethasone 12 mg PO/IV once</li>
</ol></td>
            <td style="text-align:left;" valign="top"><ol>
	<li>Olanzapine 2.5–10 mg PO daily (bedtime) on days 2, 3, and 4 </li>		
	<li>Aprepitant 80 mg PO daily on days 2 and 3 (if aprepitant PO is used on day 1)</li>		
	<li>± Dexamethasone 8 mg PO/IV daily on days 2, 3, and 4</li>
</ol></td>
        </tr>

	<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option B</b></th>
	</tr>
		<tr>
          		<td style="text-align:left;" valign="top"><ol>
			<li>Olanzapine 2.5–10 mg PO once daily (or bedtime)</li>
			<li>Palonosetron 0.25 mg IV once</li>
			<li>Dexamethasone 12 mg PO/IV once</li>
		<td style="text-align:left;" valign="top"><ol>
			<li>Olanzapine 2.5–10 mg PO daily (bedtime) on days 2, 3, and 4</li>
		</tr>

	<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option C</b></th>
	</tr>
		<tr>
          		<td style="text-align:left;" valign="top"><ol>
			<li>NK1 RA (choose one)</li>
				<ul type="square">
					<li>Aprepitant 125 mg PO once</li>
					<li>Aprepitant injectable emulsion 130 mg IV once</li>
					<li>Fosaprepitant 150 mg IV once</li>
					<li>Netupitant 300 mg / palonosetron 0.5 mg (available as fixed combination product only) PO once</li>
					<li>Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once</li>
					<li>Rolapitant 180 mg PO once</li>
				</ul>
			<li>5-HT3 RA (choose one)</li>
				<ul type="square">
					<li>Dolasetron 100 mg PO once</li>
					<li>Granisetron 10 mg SQ once, or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of anticancer therapy</li>
					<li>Ondansetron 16–24 mg PO once, or 8–16 mg IV once</li>
					<li>Palonosetron 0.25 mg IV once</li>
				</ul>
			<li>Dexamethasone 12 mg PO/IV once</li></ol>
		<td style="text-align:left;" valign="top"><ol>
			<li>Aprepitant 80 mg PO daily on days 2 and 3 (if aprepitant PO is used on day 1)</li>
			<li>Dexamethasone 8 mg PO/IV daily on days 2, 3, and 4</li>
		</tr>
		<tr>
		<th colspan="2" id="section2" style="background-color: #FF6F61;"><b>Moderate Emetic risk</b></th>
	</tr>
	<tr>
            <td class="column1"><b>Day 1</b></td>
            <td class="column2"><b>Day 2, 3,</b></td>
        </tr>
	<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option D</b></th>
	</tr>
        <tr>
            <td style="text-align:left;" valign="top"><ol>
	<li>5-HT3 RA (choose one)</li>			
		<ul type="square">
			<li>Dolasetron 100 mg PO once</li>	
			<li>Granisetron 10 mg SQ once (preferred), or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of anticancer therapy</li>
			<li>Ondansetron 16–24 mg PO once, or 8–16 mg IV once</li>
			<li>Palonosetron 0.25 mg IV once (preferred)</li>
		</ul>
	<li>Dexamethasone 12 mg PO/IV once</li>
	<td style="text-align:left;" valign="top"><ol>
			<li>Dexamethasone 8 mg PO/IV daily on days 2 and 3</li></ol>
			<p>OR</p>
			<ol><li>5-HT3 RA monotherapy</li>
				<ul type="square">
					<li>Granisetron 1–2 mg (total dose) PO daily or 0.01 mg/kg (max 1 mg) IV daily on days 2 and 3</li>
					<li>Ondansetron 8 mg PO twice daily or 16 mg PO daily or 8–16 mg IV daily on days 2 and 3</li>
					<li>Dolasetron 100 mg PO daily on days 2 and 3</li></ul></ol>
		</tr>
	<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option E</b></th>
	</tr>
        <tr>
            <td style="text-align:left;" valign="top"><ol>
		<li>Olanzapine 2.5–10 mg PO once daily (or bedtime)</li>
		<li>Palonosetron 0.25 mg IV once</li>
		<li>Dexamethasone 12 mg PO/IV once</li></ol>
	<td style="text-align:left;" valign="top"><ol>
		<li>Olanzapine 2.5–10 mg PO daily (bedtime) on days 2 and 3</li></ol></td></tr>

<tr>
		<th colspan="2" style="text-align:left;"><b>Tx option F</b></th>
	</tr>
        <tr>
            <td style="text-align:left;" valign="top"><ol>
	<li>NK1 RA (choose one)</li>			
		<ul type="square">
			<li>Aprepitant 125 mg PO once</li>	
			<li>Aprepitant injectable emulsion 130 mg IV once</li>
			<li>Fosaprepitant 150 mg IV once</li>
			<li>Netupitant 300 mg/palonosetron 0.5 mg (available as fixed combination product only) PO once</li>
			<li>Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once</li>
			<li>Rolapitant 180 mg PO once</li></ul>
	<li>5-HT3 RA (choose one)</li>
		<ul type="square">
			<li>Dolasetron 100 mg PO once</li>
			<li>Granisetron 10 mg SQ once or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of anticancer therapy</li>
			<li>Ondansetron 16–24 mg PO once, or 8–16 mg IV once</li>
			<li>Palonosetron 0.25 mg IV once</li></ul>
	<li>Dexamethasone 12 mg PO/IV once</li></ol></td>
            <td style="text-align:left;" valign="top"><ol>
	<li>Aprepitant 80 mg PO daily on days 2 and 3 (if aprepitant PO used on day 1)</li>
	<li>± Dexamethasone 8 mg PO/IV daily on days 2 and 3</li></td></tr>

	<tr>
		<th colspan="2" id="section3" style="background-color: #FF6F61;"><b>Low and Minimal Emetic Risk</b></th>
	</tr>
	<tr>
            <td colspan="2" style="text-align:left;" valign="top"><ul>(Repeat daily for multiday doses of anticancer therapy)
			<br>Dexamethasone 8–12 mg PO/IV once</br>
			<p>OR</p>
			Metoclopramide 10–20 mg PO/IV once
			<p>OR</p>
			Prochlorperazine 10 mg PO/IV once
			<p>OR</p>
			5-HT3 RA (select one)
				<ul>
				<li>Dolasetron 100 mg PO once</li>
				<li>Granisetron 1–2 mg (total dose) PO once</li>
				<li>Ondansetron 8–16 mg PO once</li></ul>
			</td></tr>
	<tr>
		<th colspan="2" id="section4" style="background-color: #FF6F61;"><b>Breakthrough Treatment for Anticancer therapy-induced Nuasea/Vomitng</b></th>
	</tr>
	<tr>
            <td colspan="2" style="text-align:left;" valign="top">Add <ins>one agent from a different drug class</ins> to the current regimen
		<ul type="square">
		<li>Atypical antipsychotic</li>
			<ul type="circle">
			<li>Olanzapine 2.5–10 mg PO daily (bedtime) (preferred, category 1)</li></ul>
		<li>Cannabinoid</li>
			<ul type="circle">
			<li>Dronabinol capsules 5–10 mg, or dronabinol PO solution 2.1–4.2 mg/m², PO 3–4 times daily</li></ul>
		<li>Other</li>
			<ul type="circle">
			<li>Haloperidol 0.5–2 mg PO/IV every 4–6 h</li>
			<li>Metoclopramide 10–20 mg PO/IV every 4–6 h</li>
			<li>Scopolamine 1.5 mg transdermal patch 1 patch every 72 h</li></ul>
		<li>Phenothiazine</li>
			<ul type="circle">
			<li>Prochlorperazine 25 mg suppository (supp) PR every 12 h or 10 mg PO/IV every 6 h</li>
			<li>Promethazine 25 mg supp PR every 6 h or 12.5–25 mg PO every 4–6 h</li></ul>
		<li>5-HT3 RA</li>
			<ul type="circle">
			<li>Dolasetron 100 mg PO daily</li>
			<li>Granisetron 1–2 mg PO daily or 1 mg PO twice a day (BID) or 0.01 mg/kg (maximum 1 mg) IV daily or 3.1 mg/24-h transdermal patch every 7 days</li>
			<li>Ondansetron 8 mg PO/IV every 8–12 h (16–24 mg total daily dose)</li></ul>
		<li>Corticosteroid</li>
			<ul type="circle">
			<li>Dexamethasone 12 mg PO/IV daily</li></ul>
		<li>Benzodiazepine</li>
			<ul type="circle">
			<li>Lorazepam 0.5–1 mg PO/sublingual (SL)/IV every 6 h</li></ul></ul>
	<br valign="bottom">Especially for patients with anticipatory, anxiety-related, or breakthrough nausea, may consider adding Lorazepam 0.5-1 mg PO or IV or SL every 6 hours <ins>PRN<ins> on days 1-4</br>
    </table>
<footer>
    <p>&copy; MAY 2025 THANAWAT KAEWSAMERTA. All rights reserved.</p>
NCCN Guidelines: Antiemesis version 1.2025 - March 27, 2025
</footer>
</body>
</html>
